MetaCap

Herbalife (HLF) vs McKesson (MCK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.

Summary

Herbalife (HLF) has outperformed McKesson (MCK) over the past year, gaining 40.1% versus a gain of 23.1%. Over five years, MCK leads with a +355.6% price change compared with -70.5% for HLF. McKesson is the larger company by market cap ($109.46 billion vs $1.35 billion), about 81.0 times the size.

On valuation, Herbalife trades at a lower forward P/E (4.2x vs 18.6x for McKesson). McKesson pays a dividend yielding 0.35%, while Herbalife does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HLF+40.11%MCK+23.09%
+125%+51%-22%
Oct 8, 20251 yearOct 8, 2026
HLF-70.21%MCK+364.66%
+417%+153%-112%
Oct 4, 20215 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HLF versus MCK key metrics
MetricHLFMCK
Share price$13.03$938.84
Market cap$1.35B$109.46B
1-day change+1.64%+0.92%
YTD return-0.54%+13.41%
1-year return+40.11%+23.09%
5-year return-70.52%+355.63%
P/E ratio (TTM)8.3025.16
Forward P/E4.2318.61
EPS (TTM)$1.57$37.31
Dividend yield0.00%0.35%
Annual dividend$0.00$3.28
Revenue (latest FY)—$403.43B
Revenue growth (YoY)—+12.36%
Net income (latest FY)—$4.76B
Gross margin—3.61%
Operating margin—1.54%
Net margin—1.18%
52-week high$20.40$999.00
52-week low$7.56$723.68
Distance from 52-week high-36.13%-6.02%
Analyst consensusnonebuy
Avg. price target upside+30.47%+4.10%
Average volume1.54M918.02K
Shares outstanding103.67M116.59M
Employees8,50041,600
SectorHealth CareHealth Care
IndustryOther PharmaceuticalsOther Pharmaceuticals

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • McKesson is about 81.0 times larger than Herbalife by market value ($109.46B vs $1.35B).
  • HLF has outperformed MCK by 17.0 percentage points over the past year.
  • McKesson trades at a higher earnings multiple (25.2x vs 8.3x trailing P/E).

About Herbalife

HLF stock →

Herbalife Ltd., together with its subsidiaries, provides health and wellness products in North America, Mexico, South and Central America, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers weight management products, including meal replacement, protein shakes, drink mixes, weight loss supplements, healthy snacks, and metabolism boosting teas; targeted nutrition products comprising functional beverages and dietary and nutritional supplements containing herbs, vitamins, minerals and other natural ingredients; energy, sports, and fitness products; and facial skin care, body care, and hair care products.

Health Care · Other Pharmaceuticals · 8,500 employees

About McKesson

MCK stock →

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions.

Health Care · Other Pharmaceuticals · 41,600 employees

HLF vs MCK FAQ

Which is bigger, Herbalife or McKesson?

McKesson (MCK) is larger, with a market capitalization of $109.46B compared with $1.35B for Herbalife (HLF).

Which stock has performed better over the past year, HLF or MCK?

HLF returned +40.11% over the past 12 months, compared with +23.09% for MCK (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, HLF or MCK?

HLF has the lower trailing P/E at 8.3, versus 25.2 for MCK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Herbalife or McKesson?

McKesson pays a dividend yielding 0.35%, while Herbalife does not currently pay a regular dividend.

Are Herbalife and McKesson in the same industry?

Yes. Both are classified in the Other Pharmaceuticals industry within the Health Care sector.

More comparisons